Drug intelligence / Profile preview

HAIC + cadonilimab + bevacizumab

Development stage: Unknown
Lead developer: Akeso
Administration: Intra-arterial, Intravenous

Overview

This entry refers to a potential drug combination involving Hepatic Arterial Infusion Chemotherapy (HAIC), cadonilimab, and bevacizumab. Based on the provided search results, specific information about **HAIC** in this exact combination is not available. The search results focus on the combination of **cadonilimab** (AK104), a bispecific antibody targeting PD-1 and CTLA-4, and **bevacizumab** (Avastin), a monoclonal antibody targeting VEGF. This combination, often with chemotherapy, has shown promising results in clinical trials for recurrent and/or metastatic cervical cancer.

Targets

VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on HAIC + cadonilimab + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAIC + cadonilimab + bevacizumab.

Explore the full profile